These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 38762716

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Myxomatous mitral valve disease and associated pulmonary hypertension might increase serum angiopoietin-2 in dogs.
    Yu H, Lee D, Chae Y, Choi M, Lee Y, Yun T, Kang BT, Yang MP, Kim H.
    Am J Vet Res; 2024 Jun 01; 85(6):. PubMed ID: 38531156
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K, Punyapornwithaya V, Tankaew P, Pongkan W, Chattipakorn N, Boonyapakorn C.
    Pol J Vet Sci; 2018 Dec 01; 21(4):673-680. PubMed ID: 30605282
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
    Kim HJ, Kim J, Kim S, Kim HJ.
    BMC Vet Res; 2023 Mar 07; 19(1):59. PubMed ID: 36882760
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease.
    Vereb M, Atkins CE, Adin D, Blondel T, Coffman M, Lee S, Guillot E, Ward JL.
    J Vet Intern Med; 2024 Mar 07; 38(1):51-60. PubMed ID: 37909399
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ, Häggström J, Møller JE, Lykkesfeldt J, Falk T, Olsen LH.
    J Vet Intern Med; 2017 Mar 07; 31(2):295-302. PubMed ID: 28132441
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
    Troia R, Sabetti MC, Crosara S, Quintavalla C, Romito G, Mazzoldi C, Fidanzio F, Cescatti M, Bertazzolo W, Giunti M, Dondi F.
    J Vet Intern Med; 2022 Nov 07; 36(6):2053-2062. PubMed ID: 36196592
    [Abstract] [Full Text] [Related]

  • 18. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG, Falk T, Teerlink T, Guðmundsdóttir HH, Sigurðardóttir S, Rasmussen CE, Olsen LH.
    Vet J; 2011 Sep 07; 189(3):349-52. PubMed ID: 20822939
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of plasma and urinary levels of 6-keto-prostaglandin F1alpha as a marker for asymptomatic myxomatous mitral valve disease in dogs.
    Rasmussen CE, Sundqvist AV, Kjempff CT, Tarnow I, Kjelgaard-Hansen M, Kamstrup TS, Sterup AL, Soerensen TM, Olsen LH.
    Vet J; 2010 May 07; 184(2):241-6. PubMed ID: 19324577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.